Hirtle Callaghan & Co’s Elevance Health ELV Stock Holding History

Hirtle Callaghan & Co’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,500	Closed	-$210K	–	164
2015 Q3	$210K	Hold	1,500	–	–	0.04%	71
2015 Q2	$246K	Buy	+1,500	New	+$240K	0.08%	62
2015 Q1	–	Sell	-110	Closed	-$14K	–	122
2014 Q4	$14K	Buy	110 +6	+6%	+$741	﹤0.01%	406
2014 Q3	$12K	Buy	104 +19	+22%	+$2.18K	﹤0.01%	447
2014 Q2	$9K	Sell	85 -20	-19%	-$2.06K	﹤0.01%	505
2014 Q1	$10K	Sell	105 -2	-2%	-$181	﹤0.01%	487
2013 Q4	$10K	Sell	107 -22	-17%	-$1.96K	﹤0.01%	466
2013 Q3	$11K	Buy	+129	New	+$11.1K	﹤0.01%	472

Other funds holding ELV

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

Hirtle Callaghan & Co's ELV Position: Q4 2015 in Review

Hirtle Callaghan & Co sold out of Elevance Health (ELV) in Q4 2015, closing a stake of 1,500 shares — an estimated $210K sold.

Hirtle Callaghan & Co first reported a position in ELV in Q3 2013 and held it in 8 quarters. The position peaked at $246K in Q2 2015. 766 funds tracked by Wall St. Rank hold ELV as of Q4 2015.

Hirtle Callaghan & Co reported no remaining Elevance Health position as of Q4 2015 after selling out during the quarter.
Hirtle Callaghan & Co sold 1,500 Elevance Health shares in Q4 2015, an estimated $210K.
Hirtle Callaghan & Co first reported a position in Elevance Health in Q3 2013 and held it in 8 quarters.
Hirtle Callaghan & Co's Elevance Health position peaked at $246K in Q2 2015.
766 funds tracked by Wall St. Rank held Elevance Health as of Q4 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q4 2015, filed 8 Feb 2016.